Historical Context: Originally developed by Novo Nordisk and evaluated by Helsinn Therapeutics in phase II clinical trials for postoperative ileus (discontinued due to insufficient therapeutic efficacy), Ipamorelin remains a gold standard in GH research
Switch to 500 mcg every other morning (EOD) as soon as Phase 1 effects are observed The every-other-day schedule reduces cumulative exposure while maintaining metabolic benefits Monitor how your body responds: appetite suppression should persist between doses at this frequency The shift from daily to EOD is not optional once effects are felt
An Ozempic diet can feel like walking through a dietary minefield when the wrong foods trigger uncomfortable side effects
weight regain after discontinuation is anticipated based on patterns seen with other GLP-1-based agents
Recently, its also been prescribed for weight loss
Sathiyamoorthy, K., Mills, E., Franzmann, T